Researchers performed saturation genome editing of the BAP1, whose dysfunction is related to cancer and impaired neurodevelopment.
FDA approves Iterum’s ORLYNVAH NDA for uUTI treatment
ORLYNVAH is indicated for the treatment of uUTIs in adult women. Credit: 9nong/Shutterstock. The US Food and Drug Administration (FDA) has approved Iterum Therapeutics‘ new
October 28, 2024